Navigation Links
E.coli outbreak prompts spinach warning

According to the FDA, an epidemic of E. coli that has left one person dead and several others sick across 8 states, may be associated with bagged fresh spinach.//

"The FDA is advising consumers not eat bagged fresh spinach at this time and that any individuals who believe they may have experienced symptoms of illness associated with E. coli 0157 contact their health care provider," Dr. David Acheson, head of the FDA's Center for Food Safety and Applied Nutrition, said in a teleconference with reporters.

Bloody diarrhea and dehydration are caused by the highly fatal strain of bacteria: E. coli O157:H7. Kids, the aged and people with weak immune system are highly susceptible to it. The children and the elderly can develop a type of kidney failure that often leads to death.

50 cases including a death due to the outbreak has been reported to the U.S. Centers for Disease Control and Prevention. Hence, Acheson explained that the outbreak was “significant”.

Connecticut, Idaho, Indiana, Michigan, New Mexico, Utah and Wisconsin are the states that have reported cases of E. coli sickness.
GY
'"/>




Page: 1

Related medicine news :

1. Fight against E.coli
2. E.coli Infection Affects Child at Nursery
3. E.coli grips Wisconsin
4. E.coli Infection Kills Idaho Toddler
5. Researcher Develops Sensor to Detect E.coli
6. E.coli-tainted spinach causes a kids death in Idaho
7. Precautionary Recall of Beef over E.coli Contamination Concerns
8. A New Cattle Vaccine to Keep E.coli Out of Food
9. El Ni?o cycles linked to cholera outbreaks
10. 3 die, 500 sickened in nations largest hepatitis A outbreak Associated Press
11. SARS outbreaks contained
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: coli outbreak prompts spinach warning

(Date:7/25/2008)... New program delivers immediate co...[24-hour telephone access to language interpreters...g multilingual solutions. , ...LLE® http://www.lle-inc.com/index.html [(Lan...ider of interpretation, translation, and language ...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
(Date:7/24/2008)...TON-SALEM, N.C. Researchers at Wake Forest Unive...-standing clinical belief that the hepatitis C vir...restore itself after HIV patients are treated with..., Hepatitis C (HCV) infection is more serious in...e, according to the Centers for Disease Control. I...
(Date:7/24/2008)...UTH, Minn., July 24 /PRNewswire-FirstCall/ -- ev3 ... to report its 2008 second quarter and,year-to-dat...second quarter,and year-to-date financial results ...ding hours., The company will host a conference c...m. Eastern Time) on Tuesday, July 29, 2008. ev3,ma...
Breaking Medicine News(10 mins):Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
... manufacturing computer chips. Now, the mega giant...thcare companies’ towards providing quality health...n others have joined hands to enable high-end heal...ntinua Health Alliance, led by Intel will seek to ...
...mputed tomography (CT), magnetic resonance imaging...he newly developed multi-modal contrast agent – Re...na-Champaign says. Use of these new agents may, i...sis and treatment of cancer, according to Kenneth ...
...he class X examination - a feat no girl of her vil...e, some 150 km from the state capital of Bhubanesw...mers. It does not have a school. Jharana Sahu use...ery day to study at a high school in nearby Kalupu...
... interact physically in a biochemical partnership ...ssels. // The study was conducted by researchers ...ne and Queen's University, Ontario, Canada and rep...dicine. The COX enzymes are well-known for their ...
Other Medicine News:Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 2Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 3Health News:New Multi-Modal Contrast Agents, A Boon For Medical Imaging 4Health News:New Role of COX Enzymes Discovered 2
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...cology Patient Accrual, DENVER, July 24 /PRNewswi...anization (RMO), has contracted with five leading ...ite management services for their,clinical trials ...The new,trials include the following disease indic...tic Breast Cancer, Metastatic Sarcoma, Chronic Mye...
(Date:7/23/2008)... print edition of Clinical Ch.../- A Roche Diagnostics-sponsored,pilo...e natriuretic peptide,(NT-proBNP) confirms the pot...in predicting the risk of cardiovascular adverse e...al anti-inflammatory drugs of,the COX inhibitor cl...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 1Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 2Origin of cells for connective tissues of skull and face challenged 3415 1Origin of cells for connective tissues of skull and face challenged 3415 2Origin of cells for connective tissues of skull and face challenged 3415 3Journal of Ultrasound In Medicine features bioeffects consensus report 20179 1Graduates Forced to Join Millions of Uninsured Americans 20174 1Graduates Forced to Join Millions of Uninsured Americans 20174 2Graduates Forced to Join Millions of Uninsured Americans 20174 3
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
...-FirstCall/ --,NeurogesX, Inc. announced today the...se 3 trial in postherpetic neuralgia (PHN).,Misha-... University,of Wisconsin in Madison and lead acade...present the results of the study in a,June 8 poste...Neuropathic Pain in Berlin, Germany. Dr. Backonja,...
Other Medicine Technology:Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4
... into the body more easily than any comparable sco...ching the lower pole calyces. Its smooth, lubricio...on of both scope and instruments. And its patented...us tip, and active secondary deflection deliver co...
...Ureteroscope permits direct visualization and acce... little or no dilation.,A tight bend radius and ...renal access, including the lower pole calyces. Du...reter and the renal pelvis. The 6.75 beveled tip f...
Smooth, contoured standard obturator provides less traumatic insertion through the urethra and into the bladder.
Electrohydraulic Lithotripsy Probe for AEH-4
Medicine Products: